Topics

Athira Pharma Announces Completion of Phase 1b Clinical Trial of NDX-1017 in Alzheimer’s Patients

00:10 EDT 2 Oct 2019 | Drugs.com

SEATTLE, Oct. 2, 2019 -- Athira Pharma, Inc., a clinical-stage company dedicated to developing first-in-class therapies for Alzheimer’s and Parkinson’s disease that are focused on regeneration, today announced the completion of the Phase...

Original Article: Athira Pharma Announces Completion of Phase 1b Clinical Trial of NDX-1017 in Alzheimer’s Patients

NEXT ARTICLE

More From BioPortfolio on "Athira Pharma Announces Completion of Phase 1b Clinical Trial of NDX-1017 in Alzheimer’s Patients"

Quick Search

Relevant Topics

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...